MERCK: NAVIGATING THE IMMUNOTHERAPY TRANSITION

Investment Analysis from June 2030

FROM: Global Intelligence Unit, Investment Analysis Division DATE: June 2030 RE: Merck Investment Thesis: Fairly Valued with Transformation Risk

EXECUTIVE SUMMARY

Merck faces a critical inflection point driven by Keytruda revenue decline (from $20.1B peak in FY2024 to $18.2B in FY2030, with further decline to $4.2B by 2035 as generics enter). The company is pursuing a deliberate transformation strategy combining Keytruda lifecycle extension, AI-accelerated drug discovery, and strategic M&A to bridge the revenue gap.

Current Valuation: - Stock price: $145.50 (as of June 2030) - Market cap: $287 billion - Forward P/E (FY2031E): 15.1x - Price/Sales (FY2030): 5.2x - Dividend yield: 2.8% - 52-week range: $138-172

Investment Thesis: Merck is fairly valued for investors willing to accept transition risk. The stock is neither cheap nor expensive relative to transformation execution probability. Upside exists if pipeline accelerates; downside if execution fails. For disciplined investors with 3-5 year horizon, Merck offers reasonable risk/reward.

SUMMARY: THE BEAR CASE vs. THE BULL CASE

THE BEAR CASE (Current Base Article Narrative): - Keytruda revenue declines precipitously post-patent cliff; generics enter 2032-2033 (earlier than expected) - Decline accelerates to $4.2B by 2035 (down 79% from $20.1B peak), faster than lifecycle extensions offset - Pipeline disappoints: only 2 major candidates achieve approval (vs. 3-4 base case); MK-4381 (metabolic) competition intensifies - Merck's AI-designed compounds (MK-7899) fail to advance beyond Phase II; costs mount - M&A integration underperforms; $10-11B acquisitions generate only 50-60% of expected synergies - FY2035 net income: $7.5B (down 18% from 2030 baseline of $9.2B) - Dividend sustainability threatened; payout ratio rises to 55-60% of earnings - Stock price 2035: $105-125 (28% downside from current $145.50) - P/E multiple compresses to 11-13x (from current 15.1x) reflecting failed transformation - Valuation: $105-130/share is fair value for risk-adjusted transformation failure scenario - Primary catalysts: Pipeline failures in 2031-2032; generic entry acceleration; M&A integration challenges

THE BULL CASE ALTERNATIVE: Dominant Metabolic Disease & Immunotherapy Platform Narrative - If MK-4381 (triple GLP-1 agonist) proves superior to Mounjaro/Zepbound and achieves 20-25% market share in $50B obesity/diabetes market by 2035 - If MK-0847 and other checkpoint inhibitors differentiate successfully in crowded market; achieve 12-15% of oncology immunotherapy market - If lifecycle extension programs for Keytruda generate $8-10B in offsetting revenue (vs. $6.5-8.4B base case) - If AI-designed compounds achieve 2-3 successful candidates advancing to Phase III by 2032+ - If M&A acquisitions achieved 85-90%+ of expected synergies through disciplined integration - FY2035 total revenue: $62-64B (vs. base case $58-60B or bear case $48-50B) - Net income 2035: $13.5B (+46% vs. 2030 baseline; +80% vs. bear case) - EBITDA margins: 36-38% (maintained despite Keytruda decline due to higher-margin pipeline products) - Stock price 2035: $215-240 (48-65% upside from current) - P/E multiple expands to 16-18x (from current 15.1x) reflecting "metabolic disease/oncology champion" narrative - Dividend grows to $3.25-3.50/share (+23-32% from current $2.65), yield improves despite stock appreciation - Entry point for bull case: $130-135 (8-10% pullback from current) - Exit point: $200-215 (metabolic market opportunity validated; MK-4381 FDA approval achieved; pipeline acceleration evident)

THE KEYTRUDA REALITY: MAGNITUDE OF CHALLENGE

Keytruda has been among the most successful drugs ever developed. Since FDA approval in 2014 for melanoma, the drug has expanded to 20+ cancer indications, generating cumulative sales exceeding $125 billion through 2030. At peak (FY2024), Keytruda represented 48% of Merck's pharmaceutical revenue.

The Decline Trajectory (Historical and Projected):

Drivers of Decline:

1. Competitive Displacement: Roche's Tecentriq, Bristol Myers' Opdivo, and next-generation checkpoint inhibitors (Regeneron, Amgen) have eroded Keytruda's peak market share from ~68% to 48-52% by June 2030. In specific indications (lung cancer, gastric cancer), Keytruda's share has fallen below 45%.

2. Generic and Biosimilar Entry: International patent expiration (2028) has resulted in generic tirzepatide entry in EU, Australia, and Canada. Price compression in international markets averaging 15-20% in the past 18 months. US patent extends to 2036, but generic entry likely by 2032-2033.

3. Pricing Pressure: Government payers increasingly exercising negotiation leverage. US Medicare negotiation reduced Keytruda price ~18% in 2029-2030 renegotiation cycle. Peak net price: $180-200K/year. Current net price: $120-140K/year. Expected further decline of 12-15% by 2032 as generic/biosimilar competition intensifies.

4. Market Saturation: Treatment penetration in developed markets approaching saturation in major indications. Growth in emerging markets constrained by pricing and access barriers.

Impact Summary: Merck faces $10-16 billion annual revenue decline from Keytruda by 2035 relative to peak. This is equivalent to ~25-30% of current total company revenue.

FINANCIAL BASELINE: MERCK IN JUNE 2030

FY2030 Estimated Financial Performance:

Revenue by Segment: - Keytruda (oncology immunotherapy): $18.2B (33%) - Other Oncology (Bridion, Lynparza, emerging): $9.8B (18%) - Infectious Disease & Vaccines: $12.4B (22%) - Primary Care & Other: $15.8B (29%) - Total Revenue: $55.2 billion

Profitability: - Gross Margin: 68% (high-margin pharma) - Operating Income: $11.7B (21.2% margin) - Net Income: $9.2B (16.7% margin) - EBITDA: $18.5B (33.5% of revenue) - Free Cash Flow (estimated): $6.8B

Balance Sheet Strength: - Total debt: $18.2B (manageable leverage) - Cash: $4.1B - Net debt/EBITDA: 0.76x (investment-grade) - Credit rating: Moody's A1, S&P A+

Shareholder Returns: - Dividend per share: $2.65 (annualized) - Dividend yield: 1.8% (increasing; expected to reach 2.8-3.0% by 2032) - Share buyback: Modest, focused on discipline ($500M-1B annually vs. historical $2-3B)

Capital Allocation Priority: 1. Dividend (sustainable, increasing) 2. R&D investment (increased to 16.8% of revenue from historical 13-14%) 3. M&A (targeted acquisitions $10-11B over 3 years) 4. Debt paydown (modest, maintaining investment-grade rating) 5. Buybacks (opportunistic, not priority)

THE PIPELINE: BETTER THAN APPEARS, BUT EXECUTION DEPENDENT

Merck's pipeline is often criticized as insufficient to replace Keytruda. This is partially fair, but obscures legitimate opportunities:

Major Pipeline Programs (Phase II/III as of June 2030):

1. MK-0847 (Oncology Immunotherapy) - Mechanism: Novel checkpoint inhibitor with improved selectivity - Status: Phase III ongoing (KEYNOTE series comparison to Keytruda) - Indication: Lung cancer, gastric cancer, renal cell carcinoma - Peak sales estimate: $2.4-2.8B (differentiated from Keytruda; potential approval 2033-2034) - Probability of approval: 55-60%

2. MK-4381 (Metabolic Disease) - Mechanism: Triple GLP-1 agonist (GLP-1 + GCG + GIP) - Status: Phase II ongoing; early data showing 15% superior weight loss vs. tirzepatide - Indication: Obesity, diabetes, cardiovascular risk reduction - Peak sales estimate: $3.2-3.8B (massive unmet need; if superior to Mounjaro, significant market capture potential) - Probability of approval: 60-65%

3. MK-5123 (NASH - Non-Alcoholic Fatty Liver Disease) - Mechanism: PPAR-delta agonist - Status: Phase II ongoing; 35% fibrosis reversal in preliminary data - Indication: Advanced NASH with fibrosis (significant population) - Peak sales estimate: $1.8-2.4B (limited competition; genuine medical need) - Probability of approval: 50-55%

4. MK-6456 (Alzheimer's Disease) - Mechanism: Amyloid-targeting (partnered with Eli Lilly) - Status: Phase II ongoing - Indication: Early symptomatic Alzheimer's - Peak sales estimate: $1.2-1.8B - Probability of approval: 45-50% (Eli Lilly partnership de-risks)

5. MK-7899 (AI-Designed Small Molecule, Cancer) - Mechanism: Novel undisclosed target (AI-designed using Exscientia) - Status: Phase I starting Q4 2030 - Indication: Oncology (specific indication TBD) - Peak sales estimate: $0.8-1.4B (highly speculative) - Probability of approval: 30-35% (early stage)

Portfolio Interpretation: - If 3 of 5 major candidates achieve approval: $7-10B in combined peak sales - If only 2 achieve approval: $4-6B in combined peak sales - Historical pharma success rates suggest 2-3 approvals is most likely outcome

Keytruda Lifecycle Extension Programs: Beyond major new drugs, Merck is extending Keytruda franchise through combinations and new indications: - Keytruda + Lenvima (renal cell, gastric): Additional $2.5-3.2B peak sales - Keytruda + targeted therapies (multiple): Additional $1.8-2.2B peak sales - New indications (prostate, pancreatic, autoimmune): Additional $2.2-3.0B peak sales

Total Lifecycle Extension Potential: $6.5-8.4B

VALUATION ANALYSIS: IS MERCK CHEAP, FAIR, OR EXPENSIVE?

Current Market Valuation (June 2030): - Stock price: $145.50 - Market cap: $287B - P/E (trailing): 16.1x - P/E (forward FY2031E): 15.1x - EV/EBITDA: 15.5x - Price/Sales: 5.2x - PEG (P/E to growth): 0.95x (assuming 16% long-term growth)

Peer Comparison: | Company | FY2030E P/E | Dividend Yield | Business Quality | |---------|------------|----------------|------------------| | Eli Lilly | 28.3x | 0.6% | Growth (GLP-1) | | Bristol Myers | 12.4x | 4.2% | Mature/Value | | AbbVie | 13.8x | 3.6% | Mature/Income | | J&J | 19.2x | 2.1% | Diversified | | Merck | 15.1x | 2.8% | Transition | | Pharma average | 16.8x | 3.1% | — |

Fair Value Estimation:

Using multiple valuation approaches:

1. Dividend Discount Model (DDM): - Current dividend: $2.65 annually - Expected growth: 6% annually for 5 years, then 3% perpetual - Cost of equity: 8.2% - Fair value: $142-158 per share

2. DCF Valuation (Free Cash Flow): Assumptions: - FY2030-2032: FCF $6.8-7.2B (modest growth as cost reductions fund R&D) - FY2033-2035: FCF $7.5-8.2B (pipeline contributions begin offsetting Keytruda decline) - Terminal FCF: $7.8B (low 2% growth) - WACC: 7.5% - Fair value: $148-165 per share

3. Comparable Company Analysis: - Merck should trade at 14-16x P/E given transition risk - FY2031E earnings estimate: $9.8B (includes pipeline optionality) - At 14-16x multiple: $137-156 per share fair value

4. Sum-of-the-Parts (SOTP) Analysis:

Note: SOTP approach is conservative, discounting optionality value. Also assumes Keytruda decline accelerates faster than lifecycle extension programs offset.

VALUATION SUMMARY: FAIR VALUE RANGE

Synthesis of approaches: - DDM: $142-158 - DCF: $148-165 - Comparable: $137-156 - SOTP: $101-120 (pessimistic scenario)

Fair value range: $140-160 per share (base case) Downside scenario: $110-130 (if pipeline disappoints, transformation fails) Upside scenario: $180-210 (if pipeline accelerates, M&A succeeds)

Current price of $145.50 = Fairly valued to slightly undervalued

INVESTMENT THESIS: WHO SHOULD OWN MERCK?

Strengths Supporting Ownership:

1. Transformation Strategy is Coherent: Keytruda lifecycle extension + pipeline acceleration + M&A is a rational response to patent cliff. Management is being realistic about challenges.

2. Financial Strength: $6.8B annual FCF, investment-grade balance sheet, and modest dividend enables funding transformation without equity dilution.

3. Pipeline Optionality: While 3-4 approvals by 2033 might not replace entire Keytruda cliff, they provide meaningful offset. Upside if approvals exceed expectations.

4. Dividend Visibility: Company has committed to maintaining and modestly growing dividend through transition. For income investors, this is attractive.

5. Valuation Discipline: At 15.1x P/E with transformation risk, valuation is not demanding premium relative to historical or peer averages.

6. Defensive Characteristic: Pharma companies provide defensive characteristics in economic downturns; earnings less cyclical than broader market.

Weaknesses Against Ownership:

1. Execution Risk: Management must execute on all fronts (pipeline acceleration, M&A integration, cost reduction). History of pharma M&A integration is mixed. Failure on any front impairs returns.

2. Pipeline Uncertainty: While MK-4381 (metabolic disease) has potential, most programs are Phase II or early Phase III. Failure rates are high. Binary risk remains.

3. Competitive Intensity: Checkpoint inhibitor market is crowded. Differentiation of new programs vs. established competitors (Opdivo, Tecentriq) is not yet proven.

4. Patent Cliff Timing Uncertainty: While $10-15B revenue decline is likely by 2035, timing and magnitude remain uncertain. Earlier/faster decline creates more severe impact.

5. Dividend Sustainability: If transformation underperforms, FCF declines materially, and dividend becomes at risk. Current valuation prices in dividend maintenance.

6. Geopolitical Risk: Heavy dependence on Asia-Pacific and emerging market manufacturing. Supply chain disruptions in Taiwan/Asia could impact profitability.

SCENARIO ANALYSIS: THREE OUTCOMES

Bull Case (30% probability): - Keytruda lifecycle extensions capture significant market (Keytruda revenue $16B by 2035, vs. $4B base case) - 4-5 major pipeline approvals by 2033 (vs. 3-4 base case) - M&A acquisitions integrate smoothly; synergies realized at 90%+ of original estimates - FY2035 revenue: $62-64B; Net income: $13.5B - Stock price by 2035: $215-240 - Annualized return from current price: 8-10% annually

Base Case (50% probability): - Keytruda lifecycle extensions provide $7-9B offsetting revenue - 3-4 major pipeline approvals by 2033-2034 - M&A acquisitions integrate at 60-70% synergy realization - FY2035 revenue: $58-60B; Net income: $11.2B - Stock price by 2035: $180-200 - Annualized return from current price: 6-8% annually

Bear Case (20% probability): - Keytruda decline accelerates; generics enter earlier than expected - Only 1-2 major pipeline approvals by 2035 (1-2 programs fail unexpectedly) - M&A acquisitions underperform; significant write-downs taken - Cost reduction insufficient; margins compress below expectations - FY2035 revenue: $48-50B; Net income: $7.5B - Stock price by 2035: $105-125 - Annualized return (decline) from current price: -3% to -1% annually

INVESTMENT RECOMMENDATION

Target Investor Profile for Merck at $145.50: - Value/income investors seeking 6-8% annual return potential - Investors with 3-5 year horizon (not seeking short-term trading) - Those comfortable with transformation risk (binary execution) - Investors seeking pharma diversification (less concentrated than Eli Lilly on single drug)

Not Suitable For: - Growth investors seeking 15%+ annual returns (Merck unlikely to deliver) - Short-term traders or those uncomfortable with volatility - Those requiring dividend certainty (transformation could pressure dividend) - ESG investors with strong governance concerns (pharma company typical governance issues)

Rating: HOLD / ACCUMULATE on Weakness

• Fair value: $140-160
• Current price: $145.50 = FAIR VALUE
• Recommendation: Hold existing positions; accumulate on any weakness below $135
• Target price (2-3 year): $175-185
• Upside/downside: +20% upside / -7% downside from current = favorable risk/reward

RISK MONITORING TRIGGERS

Sell Signals (would trigger reassessment): - Any major pipeline candidate (MK-4381, MK-5123) fails Phase II/III testing - Keytruda market share falls below 35% in major indications - M&A integration announcements with 20%+ write-down expectations - Dividend cut or suspension signal - Management changes indicating strategy shift - Stock breaks below $130

Buy Signals (would trigger overweight recommendation): - Stock declines to $125-130 on market weakness (offer good entry) - Major pipeline approval (Phase III success announcement) - Successful M&A integration with positive synergy surprises - Dividend increase announcement

DIVERGENCE COMPARISON TABLE

FINAL ASSESSMENT

BEAR CASE (20% probability): REDUCE | Target: $105-125 - Keytruda decline accelerates faster than lifecycle extensions offset - Pipeline disappoints: only 2 major candidates achieve approval (vs. 3-4 expected); MK-4381 faces competitive challenges - Generic entry accelerates to 2032 (vs. 2035+ base case); Keytruda revenue drops to $3.5-4.2B by 2035 - AI-designed compounds fail to advance significantly; R&D investments underutilized - M&A integration underperforms; write-downs taken in 2031-2032 - FY2035 net income: $7.5B (down 18% from 2030); dividend growth pressure emerges - Operating margin compresses to 18% (vs. 21% current) due to negative operating leverage - Stock re-rates to 11-13x P/E reflecting failed transformation narrative - Downside: -28% from current levels over 36 months - Suitable for: Risk management; reducing pharma transition exposure; capital reallocation - Catalysts: Pipeline failures in Phase II/III; accelerated generic entry; M&A integration challenges

BULL CASE (30% probability): BUY | Target: $215-240 - MK-4381 (metabolic disease) proves superior to competitors; achieves 18-22% market share in $50B+ TAM by 2035 - Checkpoint inhibitor franchise (MK-0847) successfully differentiates; achieves 12-15% market share despite competition - Lifecycle extensions capture $8-10B offsetting revenue through successful combinations and new indications - AI-designed compounds advance successfully; 2-3 candidates in Phase III by 2032+ - M&A acquisitions achieve 85-90%+ synergy realization; no major write-downs - FY2035 net income: $13.5B (+46% vs. 2030); operating margins expand to 28% through better product mix - Dividend grows to $3.25-3.50/share; payout ratio remains healthy at 48-52% - Stock trades at 16-18x P/E (premium to pharma average) reflecting "metabolic disease champion + oncology franchise" positioning - Upside: +48-65% from current levels over 36 months with accelerating growth trajectory - Suitable for: Growth-oriented pharma investors; metabolic disease conviction; 3-5 year horizon - Entry signal: $130-135 (8-10% pullback); MK-4381 Phase III positive data; M&A integration proceeding on schedule - Portfolio allocation: 5-7% for conviction investors; 3-4% for core pharma exposure - Key catalysts to monitor: MK-4381 Phase III interim data (2031); MK-0847 Phase III readout (2032); Q4 2030-Q3 2031 earnings guidance

BASE CASE (50% probability): HOLD / ACCUMULATE ON WEAKNESS | Target: $180-200 - Keytruda lifecycle extensions provide $7-9B offsetting revenue as expected - 3-4 major pipeline candidates achieve approval by 2033-2034 generating $5-7B combined peak sales - M&A acquisitions integrate at 60-70% synergy realization; modest disappointments managed - FY2035 net income: $11.2B (+22% vs. 2030); operating margins stabilize at 24% - Dividend growth continues at 6-8% annually; payout ratio 50-55% (sustainable) - Stock trades at 14-16x P/E reflecting "pharma transformation player" positioning - Returns: 6-8% annually from current levels (includes dividend + modest appreciation) - Suitable for: Core pharma holdings; dividend growth investors; transformation believers; 3-5 year horizon

CONCLUSION: MERCK AS CORE HOLDING

Merck represents a reasonable core holding for investors seeking pharma exposure, dividend income, and balanced risk/reward. The company is fairly valued for transformation execution. Upside exists if pipeline accelerates; downside if execution fails. The 3-5 year horizon provides reasonable window for strategy to prove out.

For long-term investors, Merck at current valuation offers acceptable risk-adjusted returns with downside protection from dividend and financial strength.

Probability-Weighted Fair Value: $155/share (0.30 × $227.5 + 0.50 × $190 + 0.20 × $115) Current Price: $145.50/share Implied Return: +6.5% to fair value, with asymmetric risk/reward (30% downside vs. 65% upside)

Recommendation: HOLD with selective accumulation on weakness below $135-140

The 2030 Report | Investment Analysis | June 2030

REFERENCES & DATA SOURCES

1. Merck 10-K Annual Report, FY2029 (SEC Filing)
2. Bloomberg Intelligence, "Biopharmaceutical R&D: Oncology and AI-Accelerated Drug Discovery," Q2 2030
3. McKinsey Global Institute, "AI in Pharma: Drug Development and Clinical Trial Optimization," 2029
4. Gartner, "AI in Pharmaceutical Development and Commercialization," 2030
5. IDC, "Worldwide Pharmaceutical IT and R&D Analytics, 2025-2030," 2029
6. Goldman Sachs Equity Research, "Merck: Oncology Portfolio and Pipeline Strength," April 2030
7. Morgan Stanley, "Pharmaceutical Sector: Patent Cliffs and Pipeline Productivity," May 2030
8. Bank of America, "Pharma Pricing: Government Pressure and Commercial Strategy," March 2030
9. Jefferies Equity Research, "Merck: Immunotherapy and Combination Therapy Growth," June 2030
10. Evercore ISI, "Pharmaceutical Innovation: R&D Efficiency and Time-to-Market," April 2030